


Development of a powerful and robust predictor for primary therapy resistance in acute myeloid leukemia to guide clinical decisions



Predictor for therapy resistance




Intensively treated acute myeloid leukemia patients



Predictor PS29MRC

- 29 genes expression markers
- favorable and unfavorable cytogenetic MRC groups



Univariate analysis

PS29MRCcont OR=2.39 p=8.63 x 10⁻⁹

PS29MRCdic OR=8.03 p=4.29 x 10⁻⁹

Multivariate analysis

PS29MRCcont OR=1.75 p=0.0011

PS29MRCdic OR=4.44 p=0.00021